Back to Search
FRANCIS GILES, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1750480950Individual
Specialties, Licenses & Credentials
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
K5957(TX)
Research & Publications (20)
New directions in the treatment of imatinib failure and/or resistance.
PMID 19621547·Semin Hematol·2009
8-other
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
PMID 19474800·Leukemia·2009
6-review
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
PMID 18346528·Semin Oncol·2008
6-review
Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.
PMID 17892367·Expert Rev Mol Diagn·2007
6-review
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML.
PMID 17577766·Leuk Lymphoma·2007
7-preclinical
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
PMID 17560285·Leuk Res·2007
3-trial
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
PMID 17223919·Br J Haematol·2007
8-other
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
PMID 17146105·J Clin Oncol·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7979 WURZBACH RD
SAN ANTONIO, TX 78229 - Phone
- (210) 450-1000
Quick Facts
- NPI
- 1750480950
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile